en زیست شناسی ملکولی Molecular Biology مقالات اصلی Original Article <div style="text-align: justify;"><strong><em>Background:</em></strong> The oral squamous cell carcinoma (OSCC) composes about 90% of all head and neck cancers.&nbsp;The toll-like receptor (TLR)+ immune cells have potential of invasion and malignancy transformation. The&nbsp;aim of this study was assessment of possible associations between clinicopathological indices and TLR2&nbsp;and TLR9 gene expression in OSCC.<br> <br> <strong><em>Methods:</em></strong> Forty-two OSCC samples with related healthy margins including 25 early and 17 advanced stages&nbsp;were gathered. The samples were classified histologically from grade I to II. The expression of TLR2 and&nbsp;TLR2 was evaluated by Real-time PCR. The patient&rsquo;s disease-free survival (DFS) and overall survival (OS)&nbsp;were analyzed using SPSS V.23 software.<br> <br> <strong><em>Results: </em></strong>The expression of TLR2 and TLR9 genes in tumor tissues (especially in grade I and II) were higher&nbsp;than healthy surgical margin tissue (p< 0.001). TLR9 expression in grade II was statistically significant than&nbsp;grade I in tumor tissue (p< 0.001). TLR9 expression in advanced stage was statistically significant in&nbsp;compare to early stage (p= 0.012). In advanced stage both overall survival (p= 0.029) and disease-free&nbsp;survival (p= 0.012) were statistically lower than early stage. The follow-up time to recurrence in advanced&nbsp;stage was statistically lower than early stage (p= 0.007).<br> <br> <strong><em>Conclusions:</em></strong> Overexpression of TLRs 2, 9 play role in the pathogenesis and tumor development of OSCC&nbsp;and can be applied as biomarker in prognostic approaches.</div> Disease-free survival, Oral squamous cell carcinoma, Overall survival, TLR2, TLR9. 200 208 http://rbmb.net/browse.php?a_code=A-10-903-1&slc_lang=en&sid=1 Reza Zare 100319475328460012174 100319475328460012174 No Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Kazem Anvari 100319475328460012175 100319475328460012175 No Department of Radiotherapy Oncology and Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Farnaz Mohajertehran 100319475328460012176 100319475328460012176 No Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran & Department of Oral and Maxillofacial Pathology, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran. Alieh Farshbaf 100319475328460012177 100319475328460012177 No Dental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Atessa Pakfetrat 100319475328460012178 100319475328460012178 No Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Amir Houshang Ansari 100319475328460012179 100319475328460012179 No Student research committee, Mashhad University of Medical Sciences, Mashhad, Iran. Maryam Ghelichli goldis.ghelichli@gmail.com 100319475328460012180 100319475328460012180 Yes Department of Oral and Maxillofacial Pathology, School of Dentistry, Golestan University of Medical Sciences, Gorgan, Iran. Nooshin Mohtasham* mohtashamn@mums.ac.ir 100319475328460012181 100319475328460012181 No Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran